Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2013 - 09 - 11

Florence - September 11, 2013 - One cell in one billion: the new Italian technology for attacking cancer


Real hope in identifying new tools in the fight against cancer. Menarini has completed its acquisition of Silicon Biosystems which has patented DEPArray ™, the first technology of its kind that is able to automatically isolate rare single cancer cells in blood while keeping them intact, alive and capable of reproducing themselves by using the principles of dielectrophoresis that enables the study of characteristics that up to now have never been revealed. The agreement with Menarini will permit Silicon Biosystems to accelerate its research and to make available new and even personalized therapeutic and diagnostic applications.

Giuseppe Giorgini, President and CEO of Silicon Biosystems: “he worsening of tumor-related diseases is determined by the onset of metastases originating from cells in circulation. The possibility of accessing circulating tumor cells (CTC) with a simple blood test provides the unique opportunity to follow the tumor’s evolution. In the blood of cancer patients, CTCs are present by a ratio of 1 per every 1 billion healthy cells. Thanks to Silicon Biosystem’s patented technologies, it is now possible to isolate single tumor cells present in the blood, analyze their biological characteristics which are often different from those of a primary tumor, and study the most appropriate and personalized therapeutic solutions.“

While Silicon Biosystems will remain a stand-alone company, it will benefit from the many synergies with the other companies of the Menarini Group, and especially with the researchers who are already working on international research projects aimed at developing innovative drugs in the oncology field.

“Once again we have decided to invest in research of the highest quality in Italy,” explains Alberto Giovanni Aleotti, Vice President of the Menarini Group, “within the framework of a system that we are sure will give us great results. In a moment such as this when the brain drain and lack of competitiveness in our country are important issues, we are very happy to take part in an initiative that moves in the opposite direction.